What is SolasCure?
Founded in 2017, SolasCure is a pioneering healthcare company dedicated to improving patient outcomes through innovative wound management. The company's core innovation, Aurase, is a hydrogel-based treatment utilizing a highly specific enzyme derived from medical maggots. This biological approach facilitates faster wound debridement, effectively reducing the burden on healthcare systems and improving the quality of life for patients suffering from chronic wounds.
By bridging the gap between traditional biological therapies and modern pharmaceutical delivery, SolasCure has established a unique market position. The company leverages its R&D capabilities to address unmet medical needs, positioning itself as a critical player in the evolving landscape of regenerative medicine and advanced wound care therapeutics.
How much funding has SolasCure raised?
SolasCure has raised a total of $35.8M across 3 funding rounds:
Series A
$20.8M
Unspecified
$1.6M
Series B
$13.4M
Series A (2021): $20.8M with participation from François Fournier, Bionova Capital, Jonathan Milner, Eva Pharma, BRAIN Biotech AG, Development Bank of Wales, and Seneca Partners
Unspecified (2021): $1.6M led by Seneca Partners
Series B (2023): $13.4M supported by Brain, Eva Pharma, Wealth Club, and Seneca Partners
Key Investors in SolasCure
Eva Pharma
A leading Egyptian pharmaceutical firm with a century of expertise, focusing on innovative healthcare solutions across oncology, neuroscience, and cardiometabolic medicine.
BRAIN Biotech AG
A prominent European supplier of biobased products and solutions, specializing in enzyme technology, strain development, and sustainable industrial processes.
Seneca Partners
An independent sponsor and specialist funder providing capital and strategic advisory services to small and medium-sized businesses across the UK and North America.
What's next for SolasCure?
Looking ahead, SolasCure is poised to leverage its recent capital infusion to scale its manufacturing capabilities and advance its clinical pipeline. The strategic focus remains on the commercialization of Aurase, with an emphasis on securing regulatory milestones and expanding distribution networks across key international markets.
The involvement of specialized biotech investors and pharmaceutical partners suggests a clear trajectory toward long-term value creation. As the company transitions from development to commercial-stage operations, the focus will likely shift toward optimizing supply chain logistics and establishing strategic partnerships with healthcare providers to integrate Aurase into standard clinical protocols for chronic wound management.
